Huang Shigao, Xing Fuqiang, Dai Yeneng, Zhang Zhiming, Zhou Guangyu, Yang Shuo, Liu Yu-Cheng, Yuan Zhen, Luo Kathy Qian, Ying Tianlei, Chu Dafeng, Liu Tzu-Ming, Deng Chu-Xia, Zhao Qi
Institute of Translational Medicine, Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China; Department of Cell Biology of National Translational Science Center for Molecular Medicine and Department of Radiation Oncology of Xijing Hospital, Fourth Military Medical University, Xi' an, China.
Institute of Translational Medicine, Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China; MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau SAR, China; Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China.
J Control Release. 2023 Oct;362:524-535. doi: 10.1016/j.jconrel.2023.09.007. Epub 2023 Sep 9.
Chimeric antigen receptor (CAR)-modified natural killer (NK) cells are recognized as promising immunotherapeutic agents for cancer treatment. However, the efficacy and trafficking of CAR-NK cells in solid tumors are hindered by the complex barriers present in the tumor microenvironment (TME). We have developed a novel strategy that utilizes living CAR-NK cells as carriers to deliver anticancer drugs specifically to the tumor site. We also introduce a time-lapse method for evaluating the efficacy and tumor specificity of CAR-NK cells using a two-photon microscope in live mouse models and three-dimensional (3D) tissue slide cultures. Our results demonstrate that CAR-NK cells exhibit enhanced antitumor immunity when combined with photosensitive chemicals in both in vitro and in vivo tumor models. Additionally, we have successfully visualized the trafficking, infiltration, and accumulation of drug-loaded CAR-NK cells in deeply situated TME using non-invasive intravital two-photon microscopy. Our findings highlight that tumor infiltration of CAR-NK cells can be intravitally monitored through the two-photon microscope approach. In conclusion, our study demonstrates the successful integration of CAR-NK cells as drug carriers and paves the way for combined cellular and small-molecule therapies in cancer treatment. Furthermore, our 3D platform offers a valuable tool for assessing the behavior of CAR cells within solid tumors, facilitating the development and optimization of immunotherapeutic strategies with clinical imaging approaches.
嵌合抗原受体(CAR)修饰的自然杀伤(NK)细胞被认为是用于癌症治疗的有前景的免疫治疗剂。然而,实体瘤中CAR-NK细胞的疗效和运输受到肿瘤微环境(TME)中存在的复杂屏障的阻碍。我们开发了一种新策略,利用活的CAR-NK细胞作为载体,将抗癌药物特异性递送至肿瘤部位。我们还引入了一种延时方法,用于在活小鼠模型和三维(3D)组织切片培养物中使用双光子显微镜评估CAR-NK细胞的疗效和肿瘤特异性。我们的结果表明,在体外和体内肿瘤模型中,当与光敏化学物质联合使用时,CAR-NK细胞表现出增强的抗肿瘤免疫力。此外,我们使用非侵入性活体双光子显微镜成功地可视化了负载药物的CAR-NK细胞在深部TME中的运输、浸润和积累。我们的研究结果强调,可以通过双光子显微镜方法在活体中监测CAR-NK细胞的肿瘤浸润情况。总之,我们的研究证明了CAR-NK细胞作为药物载体的成功整合,并为癌症治疗中的细胞和小分子联合疗法铺平了道路。此外,我们的3D平台为评估实体瘤中CAR细胞的行为提供了一个有价值的工具,有助于通过临床成像方法开发和优化免疫治疗策略。